Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NYLIA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NYLIA 1 35.
LOESTRIN FE 1.5/30 vs NYLIA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination oral contraceptive consisting of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial lining.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
One tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no medication. Continuous sequential regimen.
None Documented
None Documented
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
Norethindrone: 5-14 hours (mean ~8 hours); Ethinyl estradiol: 7-36 hours (mean ~14 hours). Clinically, steady-state is achieved within 5-7 days.
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Renal: 40-60% (as metabolites, mainly ethinyl estradiol glucuronide and sulfate conjugates and norethindrone metabolites). Biliary/fecal: 30-50% (as conjugates and metabolites).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive